No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
www.aroa.comNo one on the platform currently holds ARX.AX.
No tracked institution reports a position in ARX.AX as of their last filing.
No one on the platform has traded ARX.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.7% | — | — | — | ||
| Rev. Growth % | 19.9% | 35.1% | ||||
| Profit Margin % | 4.5% | -7.4% | ||||
| Free Cash Flow Margin % | 9.1% | -14.8% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $98M | +12.9% | $0.01 | $0.01–$0.02 | — | 3 |
| 2028 | $115M | +17.2% | $0.03 | $0.02–$0.05 | — | 3 |
| 2029 | $130M | +13.2% | $0.05 | $0.03–$0.07 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-26 | $0.00 | $0.02 | +300.2% |
| 2025-11-25 | $0.01 | $-0.00 | -131.7% |
| 2025-05-28 | $0.00 | $0.01 | +174.7% |
| 2024-11-26 | $-0.01 | $-0.01 | -37.2% |
| 2024-05-21 | $-0.00 | $-0.01 | -300.0% |
| 2023-11-28 | $-0.01 | $-0.02 | -22.6% |
| +0.00% |
| $38M |
| — |
| DXB.AXDimerix Limited | $0.23 | -2.08% | $141M | — |
| IMR.AXImricor Medical Systems, Inc. | $1.84 | -0.27% | $592M | — |
Source: Financial Modeling Prep · peers by sector/industry